Relaxin: Review of Biology and Potential Role in Treating Heart Failure |
| |
| Authors: | Sam L. Teichman Elaine Unemori John R. Teerlink Gad Cotter Marco Metra |
| |
| Affiliation: | (1) Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp., 1660 South Amphlett Boulevard, Suite 200, San Mateo, CA 94402, USA;(2) Section of Cardiology, Veterans Affairs Medical Center, University of California, San Francisco VA Medical Center, Cardiology-111C, Building 203, Room 2A-49, 4150 Clement Street, San Francisco, CA 94121-1545, USA;(3) Momentum Research, Inc, 3100 Tower Boulevard, Suite 802, Durham, NC 27707, USA;(4) Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Cardiology, University and Civil Hospital, Piazza Spedali Civili 1, 25123 Brescia, Italy |
| |
| Abstract: | Relaxin is a naturally occurring human peptide initially identified as a reproductive hormone. More recently, relaxin has been shown to play a key role in the maternal hemodynamic and renal adjustments that accommodate pregnancy. An understanding of these physiologic effects has led to the evaluation of relaxin as a pharmacologic agent for the treatment of patients with acute heart failure. Preliminary results have been encouraging. In addition, the other known biologic properties of relaxin, including anti-inflammatory effects, extracellular matrix remodeling effects, and angiogenic and anti-ischemic effects, all may play a role in potential benefits of relaxin therapy. Ongoing, large-scale clinical testing will provide additional insights into the potential role of relaxin in the treatment of heart failure. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
